Hepatitis E virus: advances and challenges

Ila Nimgaonkar,Qiang Ding,Robert E. Schwartz,Alexander Ploss
DOI: https://doi.org/10.1038/nrgastro.2017.150
2017-11-22
Abstract:Key PointsHepatitis E virus (HEV) causes varying disease severity among patient subpopulations: it is self-limiting in most young adults, but causes ∼30% mortality in pregnant women and leads to chronicity in immunocompromised patientsHEV has a broad but poorly characterized host range, and in industrialized countries it is primarily transmitted zoonotically through the consumption of undercooked meatA prophylactic vaccine against HEV exists but is currently only licensed in ChinaThere are currently no direct-acting therapy available against HEV and no non-teratogenic treatment options for pregnant women, creating a need for the development of new therapeuticsThe molecular biology of HEV remains incompletely understoodNew model systems are emerging to study HEV, but more refined models are needed to gain insights in the interactions of HEV with its host, including mechanisms of HEV pathogenesis
gastroenterology & hepatology
What problem does this paper attempt to address?